Table 4 Association between ZIC2 immunostaining results and prostate cancer phenotype in tissue micro-arrayed cancers
From: Random forest-based modelling to detect biomarkers for prostate cancer progression
Parameter | n evaluable | Negative (%) | Positive (%) | p value | Bonferroni correction |
|---|---|---|---|---|---|
All cancers | 12,581 | 76.7 | 23.3 | Â | Â |
Tumour stage | |||||
 pT2 | 7994 | 74.6 | 25.4 | < 0.0001 | 0.000006 |
 pT3a | 2837 | 78.7 | 21.3 | 0.000018 | |
 pT3b-pT4 | 1700 | 83.1 | 16.9 | 0.000029 | |
Gleason grade | |||||
 ≤ 3 + 3 | 2303 | 71.5 | 28.5 | < 0.0001 | 0.000022 |
 3 + 4 | 6700 | 75.1 | 24.9 | 0.000007 | |
 3 + 4 Tert.5 | 606 | 77.7 | 22.3 | 0.000083 | |
 4 + 3 | 1238 | 81.4 | 18.6 | 0.000040 | |
 4 + 3 Tert.5 | 907 | 85.6 | 14.4 | 0.000055 | |
 ≥ 4 + 4 | 731 | 87.1 | 12.9 | 0.000068 | |
Lymph node metastasis | |||||
 N0 | 7459 | 77.6 | 22.4 | < 0.0001 | 0.000007 |
 N+ | 932 | 86.3 | 13.7 | 0.000054 | |
Preop. PSA level (ng/ml) | |||||
 < 4 | 1479 | 75.8 | 24.2 | < 0.0001 | 0.000034 |
 4–10 | 7470 | 75.4 | 24.6 | 0.000007 | |
 10–20 | 2642 | 79.2 | 20.8 | 0.000019 | |
 > 20 | 916 | 81.3 | 18.7 | 0.000055 | |
Surgical margin | |||||
 Negative | 10,018 | 75.8 | 24.2 | < 0.0001 | 0.000005 |
 Positive | 2519 | 80.3 | 19.7 | 0.000020 | |